EZR and breast cancer: Point mutation at the palmitoylation site of CD44 reduces its raft affiliation in invasive breast cancer cells, increases CD44 co-precipitation with ezrin, thereby enhancing cell migration ability. Additionally, the palmitoylation-deficient CD44 mutant can induce epithelial-mesenchymal transition and increase cell motility.